Trelagliptin (DPP-IV inhibitors) induced Angioedema: A Case Report and Literature Review
Abstract
Angioedema is an adverse drug reaction can cause from dipeptidyl peptidase IV inhibitors (DPP-IV inhibitors) including sitagliptin, alogliptin, vildagliptin and trelagliptin. DPP-IV inhibitors used to improve glycemic control in type 2 diabetes mellitus. This adverse reaction is rare but severe and can be life-threatening therefore need to be treated and discontinued suspected drug as soon as possible. Onset of the symptom is uncertain and unpredictable so physician should monitor and provide information for their patients.
This article report about patient 60-year-old male who was diagnosed with cutaneous plasmacytoma. He was treated with VRd regimen for cutaneous plasmacytoma. Type 2 diabetes mellitus was treated with glimepiride and trelagliptin. He was admitted because of angioedema with generalized pruritus rash and abnormal complete blood count. Dermatologist and immunologist were also involved in diagnosis with trelagliptin induced angioedema and lenalidomide, fluconazole and co-trimoxazole induced early Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). Suspected drugs were discontinued and the patient was treated with prednisolone, bilastine and triamcinolone cream until his symptoms was recovered fully
References
Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516-23.
Beaudouin E, Defendi F, Picaud J, Drouet C, Ponard D, Moneret-Vautrin DA. Latrogenic angioedema associated with ACEi, sitagliptin, and deficiency of 3 enzymes catabolizing bradykinin. Eur Ann Allergy Clin Immunol. 2014;46(3):119-22.
Gülbahar O. Angioedema without wheals: a clinical update. Balkan Med J. 2021;38(2):73-81.
Noguchi Y, Murayama A, Esaki H, Sugioka M, Koyama A, Tachi T, et al. Angioedema caused by drugs that prevent the degradation of vasoactive peptides: a pharmacovigilance database study. J Clin Med. 2021;10-9.
Cassano N, Nettis E, Di Leo E, Ambrogio F, Vena GA, Foti C. Angioedema associated with dipeptidyl peptidase-IV inhibitors. Clin Mol Allergy. 2021;19(1):24-36.
Byrd JS, Minor DS, Elsayed R, Marshall GD. DPP-4 inhibitors and angioedema: a cause for concern? Ann Allergy Asthma Immunol. 2011;106(5):436-8.
Kaku K. First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2015;16(16):2539-47.
Grimshaw CE, Jennings A, Kamran R, Ueno H, Nishigaki N, Kosaka T, et al. Trelagliptin (SYR-472, Zafatek), novel once-weekly treatment for type 2 diabetes, inhibits dipeptidyl peptidase-4 (DPP-4) via a non-covalent mechanism. PLoS One. 2016;11(6):1-14.
Kalambay J, Ghazanfar H, Martes Pena KA, Munshi RA, Zhang G, Patel JY. Pathogenesis of drug induced non-allergic angioedema: a review of unusual etiologies. Cureus. 2017;9(8):1-8.
Schnyder B, Brockow K. Pathogenesis of drug allergy--current concepts and recent insights. Clin Exp Allergy. 2015;45(9):1376-83.
Hermanrud T, Bygum A, Rasmussen ER. Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV. BMJ Case Rep. 2017;1-4.
Rubinstein E, Stolz LE, Sheffer AL, Stevens C, Bousvaros A. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. BMC Gastroenterolo. 2014;14(1):71-80.
Ejikeme C, Nwachukwu C, Viechweg JL, Ejikeme I, Brescia M. DPP-IV inhibitor–associated angioedema in patient with known history of ACE inhibitor angioedema. J Investig Med. 2021;9:1-3.
Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics. 2010;20(9):532-6.
Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68(9):1781-90.
Ballester-Martínez MA, González-García C, Fleta-Asín B, Burdaspal-Moratilla A, Santón-Roldán A, Jiménez-Gómez N, et al. Cutaneous nodules as a diagnostic clue in multiple myeloma. Am J Dermatopathol. 2013;35(3):377-80.
Yoo J, Jo M, Kim MS, Jue MS, Park HJ, Choi KH. Cutaneous plasmacytoma: metastasis of multiple myeloma at the fracture site. Ann Dermatol. 2017;29(4):483-6.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพิ์เป็นลิขสิทธิ์ของวารสารโรงพยาบาลชลบุรี